Metraipolis › archive › dc_cded58284fcd

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42291898
DOI: 10.7759/cureus.108823
License (as archived): solo-consultazione
Archived: 2026-11-02T07:24:57.296Z
SHA-256 of the archived text: 6ff6488665d712870f46ff745db85eeaa50a8c71af40554d78963da35d39cb4c
Stable URL of this page: https://metraipolis.com/documento/dc_cded58284fcd

How to cite

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898 — Europe PMC (en), https://europepmc.org/article/MED/42291898 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cded58284fcd (Metraipolis archive dc_cded58284fcd, sha256 6ff6488665d712870f46ff745db85eeaa50a8c71af40554d78963da35d39cb4c)

BibTeX

@misc{dccded58284fcd,
  title = {Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42291898},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cded58284fcd; sha256 6ff6488665d712870f46ff745db85eeaa50a8c71af40554d78963da35d39cb4c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42291898. Agents can read the archived copy with the MCP tool read_document.